SUMMARY The inhibitory effect of indomethacin, 200+200 mg administered per os over 24 hours, on the prostaglandin E2 generative capacity of gastric mucosal tissue was determined in healthy male volunteers. The effect of prostaglandin synthesis inhibition on somatostatin induced suppression of food-stimulated acid secretion was tested. Peptone meal stimulated acid secretion was quantified in five healthy volunteers by intragastric titration with and without indomethacin pretreatment. Somatostatin doses of 200, 400, and 800 pmol/kg/h each significantly inhibited the peptone stimulated acid output. Indomethacin treatment, resulting in 90% inhibition of prostaglandin E2 synthesis, did not affect glucose-or peptone-stimulated acid output or modify the inhibitory action of somatostatin. Clinically, acid inhibition by somatostatin has been used to treat bleeding peptic ulcers. Ulcer haemorrhage may be preceded by an excessive use of drugs that inhibit prostaglandin synthesis such as aspirin or other non-steroidal anti-inflammatory agents. Recent observations in the rat indicate that prostaglandins mediate the inhibitory action of somatostatin on gastric acid secretion. The present results suggest that prostaglandins are not required for inhibition of gastric acid secretion by somatostatin in man.
The inhibitory action of somatostatin on gastric acid secretion has been well established in several species including man' and the rat,2 but the mechanism of its action is not fully understood. Observations in the anaesthetised rat indicate that prostaglandins mediate the inhibitory action of somatostatin on gastric acid secretion.2 Thus, somatostatin promoted gastric release of prostaglandin E2, a potent local inhibitor of acid secretion, and indomethacin, a prostaglandin synthesis inhibitor totally blocked the inhibitory action of somatostatin. The present study examines the hypothesis that prostaglandins mediate the inhibitory action of somatostatin on gastric acid secretion also in man. (Indocin, MSD) per os on the day before and on the morning of the study. A third day was identical, but no somatosta-tin or indomethacin was administered. Gastric mucosal biopsies, four from antrum and four from corpus, were taken endoscopically before and after indomethacin treatment and the biopsies were pooled respectively from each of three of the subjects, for tissue prostaglandin E2 generation assay.
Methods
The results are presented as mean and standard error of the means. The ranges of acid output data are given in brackets. Repeated measured analysis of variance was used to evaluate significances of differences between the experimental groups; p<0.05 was considered as significant.
Results
The gastric acid secretory responses to the glucose meal were 3*0±0 5 (1.6-4.6), 2-6±0-9 (0.7-6.0) and 3*7±1*0 (0.2-6.7) mmol/15 min in the control, the somatostatin-treated and the indomethacin- Figure Glucose-and Somatostatin may act locally either indirectly by interacting with hypothetical receptors on G-cells and reducing the release of gastrin,6 or directly by interacting with receptors on the parietal cells. At the cellular level, the mechanism of somatostatin action is not well understood. Its action may be because of inhibition of cyclic AMP production as this substance was strongly reduced in rat gastric glands by somatostatin.8 Some prostaglandins inhibit parietal cell cyclic AMP production9 and are potent inhibitors of acid secretion. In accordance with these observations somatostatin enhanced prostaglandin release and its inhibitory action on acid secretion could be abolished by indomethacin in the anaesthetised rat.2 Hence, prostaglandins may mediate inhibition of gastric acid secretion by somatostatin in the rat, but not in man.
The potential role of endogenous prostaglandins in the regulation of acid secretion remains controversial. Indomethacin induced inhibition of prostaglandins, verified by prostaglandin generation assay, did not affect basal or stimulated acid output which is in agreement with some investigatorsl but in contrast with others. " The present findings do not support a major physiological role for prostaglandins in the regulation of glucose-or peptonemeal-stimulated acid secretion in man.
Clinically, somatostatin has been used to treat bleeding peptic ulcers and haemorrhagic gastritis. 
